INT131161

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.54
Pain Relevance 1.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (CD58) plasma membrane (CD58)
Anatomy Link Frequency
T cell 4
effector T cells 1
CD58 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 58 99.20 Very High Very High Very High
Arthritis 215 98.88 Very High Very High Very High
rheumatoid arthritis 16 92.88 High High
methotrexate 10 89.60 High High
psoriasis 114 87.92 High High
cytokine 28 78.84 Quite High
tolerance 1 69.60 Quite High
backache 2 67.84 Quite High
Inflammatory mediators 3 63.96 Quite High
Adalimumab 12 63.04 Quite High
Disease Link Frequency Relevance Heat
Psoriasis 136 99.56 Very High Very High Very High
Disease 55 99.38 Very High Very High Very High
INFLAMMATION 59 99.20 Very High Very High Very High
Adhesions 22 98.96 Very High Very High Very High
Seronegative Spondarthritis 187 98.88 Very High Very High Very High
Skin Diseases 6 94.28 High High
Rheumatoid Arthritis 16 92.88 High High
Arthritis 36 88.44 High High
Apoptosis 8 85.28 High High
Infection 25 74.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This study supports the notion that T cell activation plays an important role in chronic inflammatory diseases and effective blockade of the LFA-3/CD2 interaction may be useful for treating PsA.
LFA-3 Binding (interaction) of in T cell associated with inflammation, disease and arthritis
1) Confidence 0.17 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 1.22 Pain Relevance 0.44
Blockade of the LFA-3/CD2 interaction, a key co-stimulatory pathway, can inhibit T-cell activation.
LFA-3 Binding (interaction) of in T-cell
2) Confidence 0.13 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 0.94 Pain Relevance 0.34
Alefacept binds competitively to the CD2 on the surface of T cells with the LFA-3 portion of the drug and efficiently interferes with LFA-3/CD2 binding and thereby T cell activation (Miller et al 1993), whereas the Fc portion of alefacept engages the immunoglobulin receptor Fc?
LFA-3 Binding (binding) of in T cell
3) Confidence 0.09 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386357 Disease Relevance 0.38 Pain Relevance 0.13
MHC class I and several adhesion molecules, including cell adhesion molecule (VCAM), intercellular adhesion molecule one (ICAM-1), activated leukocyte cell adhesion molecule (ALCAM), lymphocyte functional antigen-3 (LFA3), and some integrins can interact with their respective ligands on T-cells [65].
LFA3 Binding (interact) of in T-cells associated with adhesions
4) Confidence 0.06 Published 2010 Journal Stem Cells (Dayton, Ohio) Section Body Doc Link PMC2962904 Disease Relevance 0.39 Pain Relevance 0.03
Alefacept is a selective immunomodulating, antipsoriatic drug that blocks the LFA-3/CD2 interaction necessary for the activation and proliferation of memory effector T cells by binding to CD2 expressed on the T cell surface.
LFA-3 Binding (interaction) of in effector T cells associated with psoriasis
5) Confidence 0.03 Published 2005 Journal Expert Opin Drug Saf Section Abstract Doc Link 16255657 Disease Relevance 0.60 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox